Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azvudine vs Paxlovid in High-risk COVID-19
NCT05642910Unknown
- Sponsor
- Southeast University
- Start
- Oct 2022
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of azvudine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Southeast University. Primary endpoint: Proportion of patients RT-PCR negative for SARS-CoV-2 at 7 days. Status: unknown.
02
Drugs
azvudine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05642910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05642910.